Form 4: AbbVie Director Richard Gonzalez Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
Director Richard Gonzalez reports the vesting of performance-based shares and stock options in AbbVie, increasing his beneficial ownership.
Summary
- Richard Gonzalez, a director at AbbVie, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On February 13, 2025, performance-based shares from awards granted in 2022, 2023 and 2024 vested, resulting in the acquisition of 80,945, 33,208, 30,298 and 27,386 shares of common stock respectively.
- These shares will be issued to Gonzalez on February 28, 2025.
- Gonzalez also acquired 65,104 options to buy AbbVie common stock at an exercise price of $192.86, which become exercisable in annual increments starting February 13, 2026.
- Following these transactions, Gonzalez's direct ownership increased to 560,766 shares of AbbVie common stock and 65,104 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as it reflects the achievement of performance goals and increased alignment of management's interests with shareholders. The vesting of shares and options is a routine event, but the fact that performance targets were met is a positive signal.
Positives
- The vesting of performance-based shares suggests that AbbVie has met certain performance goals set by the Compensation Committee.
- The acquisition of stock options aligns Gonzalez's interests with those of shareholders, incentivizing him to drive company performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting of performance-based awards suggests confidence in the company's future performance.
Industry Context
Executive compensation in the pharmaceutical industry often includes performance-based equity awards to align management's interests with shareholder value. This filing reflects a typical component of executive compensation at a large pharmaceutical company like AbbVie.
Comparison to Industry Standards
- Companies like Johnson & Johnson (JNJ) and Pfizer (PFE) also utilize performance-based equity compensation for their executives.
- The specific metrics used for vesting, such as earnings per share and relative return on equity, are common in the industry to incentivize specific financial goals.
- The vesting schedules and option terms are generally in line with industry practices for executive compensation.
Stakeholder Impact
- Shareholders may view the vesting of performance-based awards positively, as it indicates that the company is achieving its goals.
- Employees may be motivated by the fact that performance targets are being met, potentially leading to further compensation opportunities.
Key Dates
| Date | Description |
|---|---|
| 02/17/2022 | Date of grant for performance share award and performance-vesting restricted stock unit award. |
| 02/16/2023 | Date of grant for performance-vesting restricted stock unit award. |
| 02/15/2024 | Date of grant for performance-vesting restricted stock unit award and employee stock options. |
| 02/13/2025 | Date of transaction for share acquisitions and stock option acquisition. |
| 02/28/2025 | Date shares will be issued to the reporting person. |
| 02/13/2026 | First date that a portion of the options become exercisable. |
| 02/13/2027 | Second date that a portion of the options become exercisable. |
| 02/13/2028 | Third date that a portion of the options become exercisable. |
| 02/12/2035 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.